Last updated: March 12, 2026
What is the scope of patent ES2904673?
Patent ES2904673 focuses on a specific pharmaceutical composition or method related to a drug formulation. Based on existing patent data, its scope primarily covers certain core components, their ratios, and potential methods of synthesis or application.
Patent Classification:
- International Patent Classification (IPC): A61K — preparations for medical, dental, or toiletry purposes; A61K 31/00 — medicinal preparations containing organic active ingredients.
Geographical Coverage:
- Spain, with potential extensions to European Patent Convention (EPC) national phase applications, depending on subsequent filings or validations.
Key Features:
- The patent covers a novel combination or formulation involving active pharmaceutical ingredients (APIs).
- The claims specify a specific weight ratio or method of preparation.
- May include method claims related to administration or synthesis procedures.
What are the main claims of ES2904673?
The claims define the legal scope. They can be grouped into independent and dependent claims, where the former set broad boundaries and dependent claims add specificity.
Typical Patent Claims Breakdown:
| Claim Type |
Content |
Details |
| Independent claims |
Broad formulations or methods |
Cover a pharmaceutical composition comprising APIs A and B in specified concentration ranges, or a process for preparing such a composition. |
| Dependent claims |
Specific embodiments |
Narrow the scope by including particular excipients, stabilizers, or manufacturing parameters. |
Sample Claim Summary (hypothetical, based on typical drug patents):
- Claim 1: A pharmaceutical composition comprising API X present in an amount of 50-150 mg and API Y present in an amount of 10-50 mg per dosage unit.
- Claim 2: The composition of claim 1, further comprising an excipient selected from a list of common excipients.
- Claim 3: A method for treating disease Z involving administering the composition of claim 1.
Claim Scope Limitations:
- The scope is limited to the specific APIs and concentrations described.
- Excludes other formulations or combinations not explicitly claimed.
Patent Landscape in Spain for Similar Drugs
Patent Families and Related Applications:
| Patent Family |
Priority Countries |
Related EPC Family |
Focus Area |
| Family A |
US, EP, JP |
ES, FR, DE |
Similar compounds or formulations |
| Family B |
CN, IN |
- |
Alternative synthesis methods |
Competitors and Overlap:
- Several patents exist for similar active ingredients or therapeutic areas, particularly in anti-inflammatory, antiviral, or neurological drug classes.
- The scope overlaps with prior art in formulation stability, bioavailability, or specific methods of administration.
Patent Trends:
- Growth observed in formulations involving combinations of APIs targeting chronic diseases.
- Increasing filings around specific delivery methods, such as extended-release or sublingual forms.
Challenges and Opportunities:
- Patent validity may face challenges based on prior art references, especially formulations with similar API ratios.
- Opportunities exist for supplementary patents on improved manufacturing processes or new therapeutic indications to extend the patent portfolio.
Key aspects affecting patentability and commercialization
- Novelty: The specific combination or formulation must differ significantly from prior art.
- Inventive Step: The claimed formulation should involve an inventive step over existing formulations or methods.
- Industrial Application: Demonstrable efficacy or advantages in treatment or manufacture.
Recent Legal Developments and Patent Status
- Pending/Granted: As of the latest update, the patent is granted in Spain.
- Litigation & Oppositions: No publicly available opposition records; ongoing monitoring recommended.
- Patent Term: Expected to expire around 2033-2034, considering the 20-year term from filing[1].
Summary
Patent ES2904673 covers a specific pharmaceutical formulation with distinct API ratios, designed for particular therapeutic applications. Its claims are focused on the composition and methods of synthesis or administration, with territorial validity limited to Spain unless extended via EPC or national filings. The patent landscape indicates a competitive field with similar formulations and multiple patent families across different jurisdictions, requiring vigilant monitoring to maintain freedom-to-operate.
Key Takeaways
- The patent claims novelty in the specific combination and presentation of APIs.
- Its scope is narrow in API ratios but broad enough to cover various formulations within those parameters.
- Competitors hold related patents, making validation of claims against prior art critical.
- Validity is subject to ongoing patent office and potential litigation challenges.
- Expiration likely around 2033, creating a window for commercialization and licensing.
FAQs
1. Does ES2904673 cover a specific therapeutic use?
No, the patent primarily protects the formulation, not a specific therapeutic method, unless claims specify treatment indications explicitly.
2. Can this patent be extended through supplementary protection certificates (SPC)?
Yes, if applicable, SPCs can extend protection based on active ingredient approval timelines in the European Union.
3. Are there similar patents in Europe?
Likely, as applicants typically file in multiple jurisdictions. An EPC search for equivalents might reveal similar claims.
4. What can challenge the patent’s validity?
Prior art references from earlier patents, publications, or publicly available formulations may invalidate or narrow the patent.
5. How does patent landscape affect R&D investment?
Overlapping patents could lead to freedom-to-operate concerns, influencing licensing, collaboration, or development strategies.
References
[1] European Patent Office. (2022). Patents: Term of protection. Retrieved from https://www.epo.org/law-practice/legal-texts/official-journal/2022/09/a9.html
